Sapreme Technologies
Business Services · Netherlands · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Yalelaan Lsi Utrecht Science Park 62, Ut...Phone Number
+31 307600976Website
www.sapreme-technologies.comRevenue
$5.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Sapreme Technologies
Sapreme is a preclinical-stage biotech company focused on developing next-generation RNA therapeutics for patients with genetically driven diseases. Their proprietary endosomal escape technology facilitates the targeted delivery of large molecules, such as ASOs and siRNAs, to intracellular targets in various tissues, including the liver, muscle, heart, and brain. The company aims to address high unmet needs in neuromuscular and cardiometabolic diseases, with a lead program targeting Duchenne muscular dystrophy. Additionally, Sapreme is seeking strategic partnerships for co-development with select pharmaceutical and biotech companies.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sapreme Technologies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Sapreme Technologies has new funding data
Congratulate Masked Content for being promoted to Masked Content at Sapreme Technologies
Product Launch: Get notified when Sapreme Technologies launches new products
Earning: See what the market has to say on Sapreme Technologies recently announced quarterly report
Click to see if Sapreme Technologies had a recent Job posting/layoffs
Check if Sapreme Technologies has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Sapreme Technologies is spiking on competitors!
Sapreme Technologies, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Sapreme Technologies
Find more new buyers
Company Profile Activity
Activity Insights
Sapreme Technologies is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Sapreme Technologies is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Sapreme Technologies.
Sapreme Technologies Tech Stack
A closer look at the technologies used by Sapreme Technologies
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
Executive Move
Board of Directors
Executive Move
Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
Sapreme Technologies News & Media
Sapreme Appoints Experienced Industry Executives, Dr. Jeanne Bolger and Dr. Andre Hoekema, to its Board of Directors
UTRECHT, The Netherlands--(BUSINESS WIRE)--Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced the appointment of experienced biopharmaceutical industry executives Jeanne Bolger, MD, and Andre Hoekema, PhD, to its Board of Directors. Both bring a wealth of executive, business and clinical development expertise from large pharmaceutical and innovative biotech companies as Sapreme now builds upon preclinical proof of conceSapreme Boosts Development of its Endosomal Escape Technology Platform and Proprietary Pipeline with EUR 15M Series A
UTRECHT, The Netherlands--(BUSINESS WIRE)--Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced that it has closed a EUR 15 million Series A financing round to accelerate the buildout of its endosomal escape technology platform and support the further progress of its proprietary pipeline and corporate development activities. Led by founding investor Aglaia Oncology Funds, together with Aglaia-associated partners, the rounSapreme Presents Promising New Preclinical Data at 17th Annual Meeting of Oligonucleotide Therapeutics Society
UTRECHT, The Netherlands--(BUSINESS WIRE)--Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, will be presenting new preclinical in vivo data on improving oligo delivery to the liver in an online poster presentation at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), held virtually from September 26th to 29th, 2021. These data highlight the capability of its proprietary endosomal escape platform to significantSapreme Appoints Henrik Luessen as Chief Business Officer
UTRECHT, The Netherlands--(BUSINESS WIRE)-- #Sapreme--Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced the appointment of Henrik L. Luessen, Ph.D., as Chief Business Officer. In this role, Dr. Luessen will advise Sapreme in its business development, partnerships and funding activities, and will report to Guy Hermans, Ph.D., Chief Executive Officer. “Henrik brings strong experience with emerging biotechnology companies
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Sapreme Technologies
Sign Up For FreeTo access detailed company insights
Sapreme is a preclinical-stage biotech company focused on developing next-generation RNA therapeutics for patients with genetically driven diseases. Their proprietary endosomal escape technology facilitates the targeted delivery of large molecules, such as ASOs and siRNAs, to intracellular targets in various tissues, including the liver, muscle, he... Read More
